Skip to main content
Top
Published in: Diabetologia 4/2016

01-04-2016 | Letter

Plasma fetuin-A triggers inflammatory changes in macrophages and adipocytes by acting as an adaptor protein between NEFA and TLR-4

Authors: Satinath Mukhopadhyay, Samir Bhattacharya

Published in: Diabetologia | Issue 4/2016

Login to get access

Excerpt

To the Editor: We read with interest the research letter entitled ‘Plasma fetuin-A does not correlate with monocyte TLR4 in humans’ by Jialal and colleagues [1]. The authors state that: ‘Studies using animal models, largely the work of Pal et al [2], have elegantly demonstrated that fetuin-A is the endogenous ligand for Toll-like receptor 4 (TLR4) via which lipids such as fatty acids induce insulin resistance, but there are no data in support of this in humans’. This is not, in fact, the case: in the paper referred to [2], our group provided data on human adipocytes from both diabetic and non-diabetic participants showing that fetuin-A acts as an endogenous ligand of TLR4 to induce insulin resistance. In another recent review, Stefan and Häring observed a significant correlation between circulating fetuin A and insulin resistance in humans [3]. …
Literature
1.
go back to reference Jialal I, Devaraj S, Adams-Huet B (2016) Plasma fetuin-A does not correlate with monocyte TLR4 in humans. Diabetologia 59:222–223CrossRefPubMed Jialal I, Devaraj S, Adams-Huet B (2016) Plasma fetuin-A does not correlate with monocyte TLR4 in humans. Diabetologia 59:222–223CrossRefPubMed
2.
go back to reference Pal D, Dasgupta S, Kundu R et al (2012) Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 18:1279–1285CrossRefPubMed Pal D, Dasgupta S, Kundu R et al (2012) Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 18:1279–1285CrossRefPubMed
3.
4.
go back to reference Chatterjee P, Seal S, Mukherjee S et al (2013) Adipocyte fetuin A contributes to macrophage migration in adipose tissue and polarization of macrophages. J Biol Chem 288:28324–28330CrossRefPubMedPubMedCentral Chatterjee P, Seal S, Mukherjee S et al (2013) Adipocyte fetuin A contributes to macrophage migration in adipose tissue and polarization of macrophages. J Biol Chem 288:28324–28330CrossRefPubMedPubMedCentral
5.
go back to reference Mukhopadhyay S, Mondal S, Kumar M, Dutta D (2014) Proinflammatory and antiinflammatory attributes of fetuin-A: a novel hepatokine modulating cardiovascular and glycemic outcomes in metabolic syndrome. Endocr Pract 20:1345–1351PubMed Mukhopadhyay S, Mondal S, Kumar M, Dutta D (2014) Proinflammatory and antiinflammatory attributes of fetuin-A: a novel hepatokine modulating cardiovascular and glycemic outcomes in metabolic syndrome. Endocr Pract 20:1345–1351PubMed
6.
go back to reference Trepanowski JF, Mey J, Varady KA (2015) Fetuin-A: a novel link between obesity and related complications. Int J Obes 39:734–741CrossRef Trepanowski JF, Mey J, Varady KA (2015) Fetuin-A: a novel link between obesity and related complications. Int J Obes 39:734–741CrossRef
Metadata
Title
Plasma fetuin-A triggers inflammatory changes in macrophages and adipocytes by acting as an adaptor protein between NEFA and TLR-4
Authors
Satinath Mukhopadhyay
Samir Bhattacharya
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 4/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-016-3866-y

Other articles of this Issue 4/2016

Diabetologia 4/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine